Oncology Peer Review On-The-Go: Examining Evidence Underlying the NCCN Guidelines for Hematologic Malignancies

Article

On this CancerNetwork® podcast, we examine the scientific evidence behind the National Comprehensive Cancer Network guidelines for hematologic malignancies.

This week, the CancerNetwork® editors review a manuscript published in the July issue of the journal ONCOLOGY® titled, “Level of Scientific Evidence Underlying the National Comprehensive Cancer Network Clinical Practice Guidelines for Hematologic Malignancies.” Corresponding author Thejaswi K. Poonacha, MD, MBA, a staff physician and hospitalist in the Department of Internal Medicine at the University of Minnesota Medical Center, joined the show to discuss the conclusions of his colleagues.

The conversation focused on the scientific evidence behind the National Comprehensive Cancer Network guidelines for hematologic malignancies, the different levels of evidence supporting the recommendations, and the main conclusions of the research. Poonacha also shared why he thinks this research is significant for the authors as well as physicians treating patients with hematologic malignancies nationwide.



Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Recent Videos
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Related Content